A Clinical Study to Evaluate the Effect of SIM01 in Female With NAFLD - Trial NCT05885373
Access comprehensive clinical trial information for NCT05885373 through Pure Global AI's free database. This phase not specified trial is sponsored by GenieBiome Limited and is currently Recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GenieBiome Limited
Timeline & Enrollment
N/A
Mar 01, 2023
Dec 31, 2023
Primary Outcome
Change in CAP score by fibroscan after taking SIM01 for 3 months
Summary
Non-alcoholic fatty liver disease is one of the most common chronic liver diseases worldwide.
 Available data indicates that probiotics may regulate the gut microbiota and improve liver
 function in females with non-alcoholic fatty liver disease. In this study, we aim to
 investigate if the synbiotics (prebiotics and probiotics) are efficacious subjects in liver
 function improvement in female subjects with Non-alcoholic fatty liver disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05885373
Non-Device Trial